MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Cost of Revenue 2011-2026 | VIVO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 145 M | 117 M | 97.4 M | 82.3 M | 82.5 M | 76.5 M | 68.9 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 145 M | 68.9 M | 95.6 M |
Quarterly Cost of Revenue Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.4 M | - | - | 42.8 M | 39.2 M | - | 26.4 M | 27.5 M | 31.4 M | 71.3 M | 28.8 M | 31.4 M | 19.8 M | 61 M | 20.2 M | 20 M | 19.9 M | 61.9 M | 19.8 M | 19.9 M | 20.3 M | 57.4 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71.3 M | 19 M | 33.2 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
RadNet
RDNT
|
1 B | $ 56.78 | -4.44 % | $ 4.27 B |  USA |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Soleno Therapeutics
SLNO
|
2.7 M | $ 30.52 | -4.12 % | $ 1.55 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Neuronetics
STIM
|
76.8 M | $ 1.4 | 4.89 % | $ 92.3 M | USA |
 |
Sotera Health Company
SHC
|
518 M | $ 13.26 | -2.1 % | $ 3.77 B | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
BioNano Genomics
BNGO
|
15.3 M | $ 1.16 | 0.87 % | $ 6.32 M | USA |
 |
Trinity Biotech plc
TRIB
|
54.9 M | $ 0.6 | -2.18 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
186 M | - | - | $ 2.68 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 23.99 | -2.87 % | $ 666 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 195.86 | -1.16 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
9.69 M | $ 8.45 | - | $ 33.7 M |  Israel |
 |
Waters Corporation
WAT
|
363 M | $ 290.62 | -3.31 % | $ 17.3 B | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
17 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
IQVIA Holdings
IQV
|
10.9 B | $ 164.81 | -2.71 % | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
473 M | $ 8.79 | -3.93 % | $ 1.91 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Personalis
PSNL
|
57.8 M | $ 6.41 | -12.43 % | $ 380 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 266.15 | -0.83 % | $ 22.1 B | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 6.45 | -1.68 % | $ 269 M | USA |
 |
Psychemedics Corporation
PMD
|
13.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
9.18 M | $ 25.64 | -5.75 % | $ 33.3 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 16.82 | -3.72 % | $ 896 M | USA |
 |
Quotient Limited
QTNT
|
20.1 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Syneos Health
SYNH
|
3.99 B | - | - | $ 4.46 B | USA |
 |
Renalytix AI plc
RNLX
|
2.13 M | - | 5.66 % | $ 22.7 M |  Britain |